Fruquintinib as Third-Line Therapy in mCRC Without Targetable Mutations, Insights From the FRESCO and FRESCO-2 Trials: Switching Mechanism of Action in a Patient Experiencing Significant Toxicity on Chemotherapy

About the Patient JT is a 71-year-old male diagnosed with metastatic rectosigmoid adenocarcinoma (Table 1). Molecular testing of a biopsy specimen revealed microsatellite stable, RAS wild-type, […]